Abbott Medical Optics Inc. announced July 3 the immediate U.S. launch following PMA approval of its Healon EndoCoat ophthalmic viscosurgical device as an aid in cataract extraction surgery and intraocular lens implantation. The clear, viscous, protective gel is injected into a patient’s eye to protect and coat the eye during surgery, Abbott explains, reducing trauma to the inside layer of the cornea and other surrounding tissues. The smaller size of the product’s delivery system and its improved ergonomics provide ease of handling for the physician, the company notes. The device is also available in Europe, Canada and New Zealand.
The vascular device maker announced 510(k) clearance for its Crux vena cava filter (VCF) for preventing pulmonary embolism July 18. Crux Biomedical Inc. described the catheter-delivered device, which is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?